New Mexico Educational Retirement Board increased its position in shares of Allergan plc (NYSE:AGN) by 2.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,129 shares of the company’s stock after purchasing an additional 900 shares during the period. New Mexico Educational Retirement Board’s holdings in Allergan were worth $5,256,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in AGN. Peloton Wealth Strategists boosted its stake in Allergan by 37.1% during the third quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock worth $2,149,000 after buying an additional 2,835 shares during the period. Sumitomo Life Insurance Co. boosted its stake in Allergan by 39.0% during the third quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock worth $3,099,000 after buying an additional 4,244 shares during the period. Colony Group LLC boosted its stake in Allergan by 9.9% during the second quarter. Colony Group LLC now owns 39,802 shares of the company’s stock worth $9,675,000 after buying an additional 3,577 shares during the period. Clear Harbor Asset Management LLC boosted its stake in Allergan by 67.7% during the third quarter. Clear Harbor Asset Management LLC now owns 5,039 shares of the company’s stock worth $1,033,000 after buying an additional 2,035 shares during the period. Finally, Alta Capital Management LLC boosted its stake in Allergan by 1.4% during the third quarter. Alta Capital Management LLC now owns 161,377 shares of the company’s stock worth $33,074,000 after buying an additional 2,151 shares during the period. Hedge funds and other institutional investors own 79.76% of the company’s stock.
In other news, Director Chris W. Bodine purchased 3,030 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was bought at an average price of $164.77 per share, for a total transaction of $499,253.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Meury sold 11,807 shares of Allergan stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders purchased 17,630 shares of company stock valued at $2,890,057 in the last quarter. 0.36% of the stock is owned by insiders.
Allergan plc (NYSE AGN) opened at $162.46 on Tuesday. The company has a quick ratio of 1.88, a current ratio of 2.04 and a debt-to-equity ratio of 0.41. Allergan plc has a 12 month low of $157.70 and a 12 month high of $256.80. The company has a market cap of $54,134.55, a P/E ratio of -12.11, a PEG ratio of 1.17 and a beta of 1.19.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The business had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. During the same quarter last year, the firm posted $3.90 earnings per share. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. sell-side analysts expect that Allergan plc will post 15.56 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.77%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is currently -20.86%.
Several research analysts have weighed in on AGN shares. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $275.00 target price on shares of Allergan in a research note on Monday, October 16th. Credit Suisse Group set a $243.00 target price on shares of Allergan and gave the stock an “outperform” rating in a research note on Tuesday, October 17th. UBS Group set a $255.00 target price on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Deutsche Bank set a $251.00 target price on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Finally, Zacks Investment Research lowered shares of Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. Allergan presently has a consensus rating of “Buy” and a consensus target price of $227.23.
ILLEGAL ACTIVITY WARNING: “Allergan plc (AGN) Position Raised by New Mexico Educational Retirement Board” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/allergan-plc-agn-position-raised-by-new-mexico-educational-retirement-board.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.